Growth was studied in 68 children aged 2-12 years with atopic eczema. Height SD scores were significantly correlated with the surface area of skin affected by eczema. The mean height of41 patients with less than 50/o of their skin surface affected (group I) was normal (mean SD score -0.11). The 27 children with more than 50% of their skin affected (group II) were sigiicantly shorter (SD score -0.83) and were also short allowing for their parental target height. The predicted heights were also normal in group I but were lower than expected in group H. Regression analysis suggested that height was most dependent on parental height. The extent of the disease had a significant additional effect, whereas dietary treatment and treatment with topical steroids had only marginal additional effects. The growth of children with eczema affecting less than 50% of the skin surface area appears to be normal, and impaired growth is confined to those with more extensive disease.
The growth of children with atopic eczema has attracted little attention. In one cross sectional study of 89 patients aged [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] years requiring regular hospital attendance, the height of nine (10%) children was below the third centile.' When corrected for mid-parental height, the height of 16 (23%) of 69 patients aged 2-9 years was below the tenth centile.' Those with short stature tended to have extensive eczema, to use more potent topical steroids, and to have more severe asthma, but these trends were not statistically significant. A postal questionnaire study which relied on home measurement of 128 patients with atopic eczema up to 16 years of age found the height of patients to be significantly less than that of their unaffected friends. 2 The aim of this study was to examine the growth of children with eczema confined to the age of the mid-childhood period of growth34 which avoids the confounding variability of the cm to the maternal height for a boy, or after subtracting 12 6 cm from the paternal height for a girl. The parental target height SD score was then calculated. 8 The percentage ofskin surface area affected by erythema, vesicles, and crusts was routinely recorded at each outpatient visit. In this study we used the maximum figure ever recorded for each patient. All patients had received topical corticosteroids, which were scored according to the British National Formulary classification'0 as category 4 [axis and bronchodilators. [yses, comparing height SD score as the (5%) were below the third centile allowing for endent variable with several explanatory mid parental height. In these two children, ables, was performed using the SPSS pro-although the area ofeczema was limited, the skin n.'3 Data are presented as either median lesions were particularly severely inflamed. Of ge) or mean (SD).
the 27 patients in group II the height of eight (30%) was below the third centile allowing for their parents. Four of the eight had received an ults elemental diet and one had also received systemic median age of the 68 patients was 6-2 years steroids. Two patients in group I (5%) and none tge 2-3-11-9) and the median surface area in group II had a height above the 97th centile cted by eczema was 30% (range he figure shows that there was a highly When calculating predicted heights (table 3) ificant correlation between height SD score those of the group II patients were not significsurface area of eczema (Spearman's correla-antly less than the mid-parental heights (p= coefficient rs=0-42; p=0003). There 0-08). The predicted heights were, however, eared to be two groups of patients; the height below those of the group I patients despite having taller parents (U= 111; p=0-18). score (additional r2=0 03; p=007) and diet score (additional r2=0) had only a marginal additional effect and no effect respectively. Asthma score and duration of disease had no additional effect. Discussion Impaired growth is a recognised complication of many chronic diseases during childhood, including asthma. '4 5 In contrast with the latter, however, the poor growth of some children with atopic eczema has received scant attention. As in two previous reports on the subject,' 2 this study used patients who attended a tertiary referral centre and who were therefore a highly selected group.
In contrast with the previous studies we have been able to show that the growth of children with eczema is statistically significantly related to the severity of disease. The height of patients in whom eczema affected less than 50% of their body surface area was normal, compared with standard data and with their parents. Those with eczema which affected more than 50% of their body surface area, however, had notable growth impairment. The mean height SD score of -0-83 in patients in this group implies that their heights were centred around the 25th rather than the 50th centile. Eight ofthe 27 (30%) patients in the latter group had a height less than the third centile when corrected for their parents' height.
The previous finding of more generalised short stature in a group of children with atopic eczema compared with control children2 is probably explained by the inclusion of a small number of severe cases. In addition, the overall figure of height SD score in their study of -0 45 was less than the figure of -0-26 found in the present study, and the former may have been due to the inclusion of adolescent patients with pubertal delay. Delay in puberty would also explain the previous finding of a relatively lower sitting height than subischial leg length in patients with atopic eczema.' It is known that there is less growth in the spine than there is in the legs in patients with pubertal delay. 16 The regression analysis showed that apart from parental heights, the largest influence on height SD score was the surface area of skin affected by eczema. The reason for this association is unclear. There appeared to be no independent effect of asthma, and little effect of strength of steroid preparation or use of exclusion diets. Any effect of the latter two may have been masked by the fact that the most severely affected patients tended to receive the strongest steroid preparations and the most stringent diets.
Our data suggest that children with atopic eczema which affects less than 50% of the skin surface area have a normal height, but that those with more extensive disease may have impaired growth. The cause of this impaired growth has not been identified.
